Quantisnow Logo
Dashboard

SEC Form SC 13G/A filed by Gritstone bio Inc. (Amendment)

$GRTS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $GRTS alert in real time by email
SC 13G/A 1 d781888dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

 

 

Gritstone bio, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

39868T 105

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

Frazier Life Sciences Public Fund, L.P.

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

0 shares

    6.   

Shared Voting Power

 

0 shares

    7.   

Sole Dispositive Power

 

0 shares

    8.   

Shared Dispositive Power

 

0 shares

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

0 shares

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

0.0%

12.   

Type of Reporting Person (see instructions)

 

PN

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

FHMLSP, L.P.

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

0 shares

    6.   

Shared Voting Power

 

0 shares

    7.   

Sole Dispositive Power

 

0 shares

    8.   

Shared Dispositive Power

 

0 shares

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

0 shares

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

0.0%

12.   

Type of Reporting Person (see instructions)

 

PN

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

FHMLSP, L.L.C.

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

0 shares

    6.   

Shared Voting Power

 

0 shares

    7.   

Sole Dispositive Power

 

0 shares

    8.   

Shared Dispositive Power

 

0 shares

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

0 shares

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

0.0%

12.   

Type of Reporting Person (see instructions)

 

OO

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

Frazier Healthcare VII, L.P.

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

0 shares

    6.   

Shared Voting Power

 

802,258 shares (1)

    7.   

Sole Dispositive Power

 

0 shares

    8.   

Shared Dispositive Power

 

802,258 shares (1)

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

802,258 shares (1)

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

0.8% (2)

12.   

Type of Reporting Person (see instructions)

 

PN

 

(1)

Consists of 802,258 shares of Common Stock held directly by Frazier Healthcare VII, L.P. FHM VII, L.P. is the general partner of Frazier Healthcare VII, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Nader Naini, Patrick J. Heron, James N. Topper, Nathan Every, and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII, L.P.

(2)

Based on 95,342,055 shares of Common Stock outstanding on November 6, 2023 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 8, 2023.

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

Frazier Healthcare VII-A, L.P.

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

0 shares

    6.   

Shared Voting Power

 

228,620 shares (1)

    7.   

Sole Dispositive Power

 

0 shares

    8.   

Shared Dispositive Power

 

228,620 shares (1)

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

228,620 shares (1)

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

0.2% (2)

12.   

Type of Reporting Person (see instructions)

 

PN

 

(1)

Consists of 228,620 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P. FHM VII, L.P. is the general partner of Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Nader Naini, Patrick J. Heron, James N. Topper, Nathan Every, and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII-A, L.P.

(2)

Based on 95,342,055 shares of Common Stock outstanding on November 6, 2023 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 8, 2023.

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

FHM VII, L.P.

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

0 shares

    6.   

Shared Voting Power

 

1,030,878 shares (1)

    7.   

Sole Dispositive Power

 

0 shares

    8.   

Shared Dispositive Power

 

1,030,878 shares (1)

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,030,878 shares (1)

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

1.1% (2)

12.   

Type of Reporting Person (see instructions)

 

PN

 

(1)

Consists of (i) 802,258 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii) 228,620 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P (collectively, the “FH Shares”). FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Nader Naini, Patrick J. Heron, James N. Topper, Nathan Every, and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the FH Shares.

(2)

Based on 95,342,055 shares of Common Stock outstanding on November 6, 2023 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 8, 2023.

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

FHM VII, L.L.C.

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

0 shares

    6.   

Shared Voting Power

 

1,030,878 shares (1)

    7.   

Sole Dispositive Power

 

0 shares

    8.   

Shared Dispositive Power

 

1,030,878 shares (1)

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,030,878 shares (1)

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

1.1% (2)

12.   

Type of Reporting Person (see instructions)

 

OO

 

(1)

Consists of (i) 802,258 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii) 228,620 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P (collectively, the “FH Shares”). FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Nader Naini, Patrick J. Heron, James N. Topper, Nathan Every, and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the FH Shares.

(2)

Based on 95,342,055 shares of Common Stock outstanding on November 6, 2023 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 8, 2023.

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

James N. Topper

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

United States Citizen

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

61,307 shares (1)

    6.   

Shared Voting Power

 

1,030,878 shares (2)

    7.   

Sole Dispositive Power

 

61,307 shares (1)

    8.   

Shared Dispositive Power

 

1,030,878 shares (2)

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,092,185 shares (1)(2)

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

1.1% (3)

12.   

Type of Reporting Person (see instructions)

 

IN

 

(1)

Consists of 61,307 shares of Common Stock held directly by James N. Topper.

(2)

Consists of (i) 802,258 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii) 228,620 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P (collectively, the “FH Shares”). FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Nader Naini, Patrick J. Heron, James N. Topper, Nathan Every, and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the FH Shares.

(3)

Based on 95,342,055 shares of Common Stock outstanding on November 6, 2023 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 8, 2023.

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

Patrick J. Heron

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

United States Citizen

Number of Shares Beneficially  Owned by

Each

Reporting

Person

With:

     5.   

Sole Voting Power

 

31,307 shares (1)

    6.   

Shared Voting Power

 

1,030,878 shares (2)

    7.   

Sole Dispositive Power

 

31,307 shares (1)

    8.   

Shared Dispositive Power

 

1,030,878 shares (2)

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,062,185 shares (1)(2)

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

1.1% (3)

12.   

Type of Reporting Person (see instructions)

 

IN

 

(1)

Consists of (i) 31,307 shares of Common Stock held directly by The Heron Living Trust dated 11/30/2004, which Patrick J. Heron is the trustee and has voting and investment power over such shares.

(2)

Consists of (i) 802,258 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii) 228,620 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P (collectively, the “FH Shares”). FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Nader Naini, Patrick J. Heron, James N. Topper, Nathan Every, and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the FH Shares.

(3)

Based on 95,342,055 shares of Common Stock outstanding on November 6, 2023 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 8, 2023.

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

Albert Cha

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

United States Citizen

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

0 shares

    6.   

Shared Voting Power

 

0 shares

    7.   

Sole Dispositive Power

 

0 shares

    8.   

Shared Dispositive Power

 

0 shares

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

0 shares

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

0.0%

12.   

Type of Reporting Person (see instructions)

 

IN

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

James Brush

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

United States Citizen

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

0 shares

    6.   

Shared Voting Power

 

0 shares

    7.   

Sole Dispositive Power

 

0 shares

    8.   

Shared Dispositive Power

 

0 shares

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

0 shares

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

0.0%

12.   

Type of Reporting Person (see instructions)

 

IN

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

Nader Naini

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

United States Citizen

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

0 shares

    6.   

Shared Voting Power

 

1,030,878 shares (1)

    7.   

Sole Dispositive Power

 

0 shares

    8.   

Shared Dispositive Power

 

1,030,878 shares (1)

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,030,878 shares (1)

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

1.1% (2)

12.   

Type of Reporting Person (see instructions)

 

IN

 

(1)

Consists of (i) 802,258 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii) 228,620 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P (collectively, the “FH Shares”). FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Nader Naini, Patrick J. Heron, James N. Topper, Nathan Every, and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the FH Shares.

(2)

Based on 95,342,055 shares of Common Stock outstanding on November 6, 2023 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 8, 2023.

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

Brian Morfitt

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

United States Citizen

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

5,722 shares (1)

    6.   

Shared Voting Power

 

1,030,878 shares (2)

    7.   

Sole Dispositive Power

 

5,722 shares (1)

    8.   

Shared Dispositive Power

 

1,030,878 shares (2)

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,036,600 shares (1)(2)

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

1.1% (3)

12.   

Type of Reporting Person (see instructions)

 

IN

 

(1)

Consists of 5,722 shares of Common Stock held directly by Brian Morfitt.

(2)

Consists of (i) 802,258 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii) 228,620 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P (collectively, the “FH Shares”). FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Nader Naini, Patrick J. Heron, James N. Topper, Nathan Every, and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the FH Shares.

(3)

Based on 95,342,055 shares of Common Stock outstanding on November 6, 2023 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 8, 2023.

CUSIP No. 39868T 105

 

 1.   

Names of Reporting Persons

 

Nathan Every

 2.   

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐  (b) ☒

 

 3.   

SEC USE ONLY

 

 4.   

Citizenship or Place of Organization

 

United States Citizen

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person With:

     5.   

Sole Voting Power

 

8,221 shares (1)

    6.   

Shared Voting Power

 

1,030,878 shares (2)

    7.   

Sole Dispositive Power

 

8,221 shares (1)

    8.   

Shared Dispositive Power

 

1,030,878 shares (2)

 9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,039,099 shares (1)(2)

10.   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

 

☐

11.   

Percent of Class Represented by Amount in Row 9

 

1.1% (3)

12.   

Type of Reporting Person (see instructions)

 

IN

 

(1)

Consists of 8,221 shares of Common Stock held directly by Nathan Every.

(2)

Consists of (i) 802,258 shares of Common Stock held directly by Frazier Healthcare VII, L.P. and (ii) 228,620 shares of Common Stock held directly by Frazier Healthcare VII-A, L.P (collectively, the “FH Shares”). FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Nader Naini, Patrick J. Heron, James N. Topper, Nathan Every, and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the FH Shares.

(3)

Based on 95,342,055 shares of Common Stock outstanding on November 6, 2023 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 8, 2023.

Item 1(a).    Name of Issuer: Gritstone bio, Inc.
Item 1(b).    Address of Issuer’s Principal Executive Offices: 5959 Horton Street, Suite 300, Emeryville, California 94608
Item 2(a).   

Name of Person Filing:

 

The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

 

Frazier Healthcare VII, L.P. (“FH-VII”)

Frazier Healthcare VII-A, L.P. (“FH-VIIA”)

FHM VII, L.P. (“FHM-VII L.P.”)

FHM VII, L.L.C. (“FHM-VII LLC”)

Frazier Life Sciences Public Fund, L.P. (“FLSPF”)

FHMLSP, L.P.

FHMLSP, L.L.C.

James N. Topper (“Topper”)

Patrick J. Heron (“Heron”)

Nader Naini (“Naini”)

Nathan Every (“Every”)

Brian Morfitt (“Morfitt”)

Albert Cha (“Cha”)

James Brush (“Brush” and together with Topper, Heron, Naini, Every and Brush, the “Members”)

Item 2(b).   

Address of Principal Business Office or, if none, Residence:

 

The address and principal business office of the Reporting Persons is:

 

c/o Frazier Life Sciences Management, L.P.

70 Willow Road, Suite 200

Menlo Park, CA 94025

Item 2(c).    Citizenship:      
   Entities:   FH-VII    -    Delaware, U.S.A.
  

    FH-VIIA

    -    Delaware, U.S.A.
  

    FHM-VII L.P.

    -    Delaware, U.S.A.
  

    FHM-VII LLC

    -    Delaware, U.S.A.
  

    FLSPF

    -    Delaware, U.S.A.
  

    FHMLSP, L.P.

    -    Delaware, U.S.A.
  

    FHMLSP, L.L.C.

    -    Delaware, U.S.A.
   Individuals:   Topper    -    United States Citizen
  

    Heron

    -    United States Citizen
  

    Naini

    -    United States Citizen
  

    Every

    -    United States Citizen
  

    Morfitt

    -    United States Citizen
  

    Cha

    -    United States Citizen
  

    Brush

    -    United States Citizen
Item 2(d).    Title of Class of Securities: Common Stock
Item 2(e).    CUSIP Number: 39868T 105
Item 3.    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
(a)   

☐   Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)   

☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)   

☐   Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)   

☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)   

☐   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

  (f)   ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     (g)   ☐    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
  (h)   ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  (i)   ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
  (j)   ☐    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
  (k)   ☐    Group, in accordance with §240.13d–1(b)(1)(ii)(K).
       If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

 

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

 

  (a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

 

  (b)

Percent of Class: See Row 11 of cover page for each Reporting Person

 

  (c)

Number of shares as to which the person has:

 

  (i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

 

  (ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

 

  (iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

 

  (iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

 

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

 

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G amendment.

 

Item 9.

Notice of Dissolution of a Group

Not applicable.

 

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 13, 2024     FRAZIER HEALTHCARE VII, L.P.
    By FHM VII, L.P., its general partner
    By FHM VII, L.L.C., its general partner
    By:   /s/ Steve R. Bailey
      Steve R. Bailey, Chief Financial Officer
Date: February 13, 2024     FRAZIER HEALTHCARE VII-A, L.P.
    By FHM VII, L.P., its general partner
    By FHM VII, L.L.C., its general partner
    By:   /s/ Steve R. Bailey
      Steve R. Bailey, Chief Financial Officer
Date: February 13, 2024     FHM VII, L.P.
    By FHM VII, L.L.C., its general partner
    By:   /s/ Steve R. Bailey
      Steve R. Bailey, Chief Financial Officer
Date: February 13, 2024     FHM VII, L.L.C.
    By:   /s/ Steve R. Bailey
      Steve R. Bailey, Chief Financial Officer
Date: February 13, 2024     FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
    By: FHMLSP, L.P., its General Partner
    By: FHMLSP, L.L.C., its General Partner
    By:   /s/ Steve R. Bailey
      Steve R. Bailey, Chief Financial Officer
Date: February 13, 2024     FHMLSP, L.P.
    By: FHMLSP, L.L.C., its General Partner
    By:   /s/ Steve R. Bailey
      Steve R. Bailey, Chief Financial Officer
Date: February 13, 2024     FHMLSP, L.L.C.
    By:   /s/ Steve R. Bailey
      Steve R. Bailey, Chief Financial Officer
Date: February 13, 2024     By:   *
      James N. Topper

Date: February 13, 2024     By:   *
      Patrick J. Heron
Date: February 13, 2024     By:   *
      Nader Naini
Date: February 13, 2024     By:   *
      Nathan Every
Date: February 13, 2024     By:   *
      Brian Morfitt
Date: February 13, 2024     By:   **
      Albert Cha
Date: February 13, 2024     By:   **
      James Brush
Date: February 13, 2024     *By:   /s/ Steve R. Bailey
      Steve R. Bailey, as Attorney-in-Fact

 

*

This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**

This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

Exhibit Index

 

Exhibit A -    Agreement regarding filing of joint Schedule 13G.

 
Get the next $GRTS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GRTS

DatePrice TargetRatingAnalyst
10/1/2024Mkt Outperform → Mkt Perform
JMP Securities
2/28/2024$4.00Mkt Outperform
JMP Securities
3/31/2023Outperform
Evercore ISI
3/28/2023$8.00Buy
B. Riley Securities
10/31/2022$6.00Overweight
Piper Sandler
8/22/2022$2.00Neutral → Sell
Goldman
12/15/2021$15.00Neutral
Goldman
10/15/2021$20.00Buy
BTIG Research
More analyst ratings

$GRTS
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure

    Voluntarily Files for Chapter 11 Restructuring Strategic Alternatives Process Continues with Interest from Parties Gritstone bio, Inc. (NASDAQ:GRTS) ("Gritstone" or the "Company"), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Gritstone intends to use the court-administered restructuring process to preserve value and support its ongoing strategic alternatives process. The Company is in discussions with a party to act as a stalking horse bidder or plan sponsor and intends to

    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

    --Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.62 [95% CI, 0.23-1.70]) -- -- Strength of neoantigen specific T cell responses in GRANITE patients appears to associate with progression-free survival -- GRANITE was generally well-tolerated with no treatment discontinuations due to adverse events– -- Overa

    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

    -- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer -- -- Presentations at AACR 2024 and ESCMID Global 2024 demonstrate the broad potential of Gritstone's oncology and infectious disease vaccines -- -- Cash, cash equivalents, marketable securities and restricted cash of $61.7 million as of June 30, 2024 -- EMERYVILLE, C

    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$GRTS
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GRTS
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GRTS
 SEC Filings

See more

$GRTS
 Leadership Updates

Live Leadership Updates

See more

  • Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors

    EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The company also announced that Steve Krognes will not stand for re-election at the 2024 Annual Meeting. "We are excited to welcome Stephen Webster to our Board of Directors at this important and excit

    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

    -- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine vectors, EDGE has demonstrated best-in-class potential in identifying neoantigens capable of eliciting T cell immune responses for robust and durable immunity -- EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today presented an upd

    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors

    EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company's strategic initiatives and commercialization efforts. Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio, Inc (NASDAQ:GRTS). Recognized by Pharmaceutical Executive magazine as a leading business executive in the pharma and biotech industries, Dr. Hawryluk has played key roles in bridging the gap between scientific discovery and the commercial application of scientific breakthroughs. As a named invento

    $GRTS
    $POAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties

$GRTS
 Financials

Live finance-specific insights

See more

  • Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024

    -- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. To access by phone, dial: 1-877-407-4018Conference ID: 13746126To access by webcast, visit: https://viavid.webcasts.com/starthere.jsp?ei=1667088&tp_key=d0e680f7aa While not required, it is recommended yo

    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates

    -- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (personalized vaccine in first-line metastatic microsatellite-stable colorectal cancer [MSS-CRC]) to date; 71 of 80 patients (initial target) enrolled as of May 10, 2023 -- -- Gritstone prioritizing GRANITE; expanding Phase 2 from 80 to 100 patients, enrollment completion expected in 3Q2023, preliminary data on approximately 50 patients expected in 1Q2024 -- -- Cash, cash equivalents, marketable securities, and restricted cash of $153.2 million as of March 31, 2023 -- -- Gritstone to host conference call today at 4:30pm ET -- EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ

    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Gritstone bio to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 11, 2023

    EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report its first quarter 2023 financial results and provide a corporate update following market close on Thursday, May 11, 2023. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. Live Conference Call & WebcastToll Free: 1-888-999-6281International: 1-848-280-6550Conference ID: 1754341Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1612896&tp_key=c6c637ac24 While not required, it is recommended you join five minutes prior to the

    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$GRTS
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more